Biospecifics Tech Cp (BSTC) 37.55 $BSTC AstraZeneca

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 3:13 AM

Biospecifics Tech Cp (BSTC) 37.55 $BSTC

AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 37.55 (+0.96), AZN: 32.60 (-0.21), OHRP: 2.77 (-0.09)

Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:45AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) was a big mover last session, as the company saw its shares rise over 8% on the day.
BSTC: 37.55 (+0.96), DPRX: 12.79 (+0.09)

What Makes Collegium Pharmaceutical (COLL) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:25AM CDT
Collegium Pharmaceutical (COLL) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 37.55 (+0.96), COLL: 8.83 (+0.50)

The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
LCI: 33.37 (-0.49), BSTC: 37.55 (+0.96), MYL: 41.92 (-0.44), USNA: 136.35 (-0.39), TEVA: 50.90 (+0.51)

Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:32AM CDT
Jazz Pharmaceuticals (JAZZ) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 37.55 (+0.96), JAZZ: 123.31 (-0.52)

Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 33.37 (-0.49), ENDP: 20.23 (-0.47), VRX: 29.12 (+0.09), BSTC: 37.55 (+0.96), MYL: 41.92 (-0.44), TEVA: 50.90 (+0.51), USNA: 136.35 (-0.39)

New Strong Buy Stocks for August 22nd
Tirthankar Chakraborty - Zacks Investment Research - Mon Aug 22, 7:36AM CDT
New Strong Buy Stocks for August 22nd
BSTC: 37.55 (+0.96), DTLK: 9.98 (+0.24), SNP: 71.34 (-0.03), COTV: 32.53 (-0.71), AEIS: 45.00 (+1.05)

Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Up 6.3%
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:45AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BSTC: 37.55 (+0.96), CPRX: 0.96 (-0.05)

BioSpecifics Technologies Corp. Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2016 and provided a corporate update.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
PR Newswire - Tue Aug 02, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 9, 2016 to report its second quarter 2016 financial results and to provide a corporate update.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
PR Newswire - Mon Jun 13, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC) today announced positive, statistically significant top-line results from a placebo-controlled, double-blind Phase II clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma. The trial met its primary endpoint of reduction in the visible surface area of the target lipomas relative to placebo, as determined by caliper, at six months post injection (p<0.0001), and also met all secondary efficacy endpoints. There were no serious adverse events reported during the trial.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:00 a.m. ET in New York, NY.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
PR Newswire - Tue May 31, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the publication of data highlighting the efficacy of collagenase clostridium histolyticum (CCH) for the treatment of uterine fibroids in the May 2016 issue of the American Journal of Obstetrics & Gynecology in an article titled, "Loss of Stiffness in Collagen-Rich Uterine Fibroids after Digestion with Purified Collagenase Clostridium Histolyticum." The data show that highly purified CCH can reduce the stiffness of human uterine fibroids ex-vivo and potentially decrease their size.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. to Present at the 2016 UBS Global Healthcare Conference
PR Newswire - Wed May 18, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 3:00 p.m. ET in New York, NY.
BSTC: 37.55 (+0.96)

New Strong Sell Stocks for May 13th
Zacks Equity Research - Zacks Investment Research - Fri May 13, 9:48AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AIXG: 6.16 (unch), BSTC: 37.55 (+0.96), AZZ: 66.62 (+0.19), ASB: 19.68 (-0.16), AHT: 6.76 (-0.21)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 37.55 (+0.96), ARQL: 1.40 (-0.08), APRI: 0.34 (-0.01), RPRX: 2.00 (-0.03)

Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 37.55 (+0.96), JAZZ: 123.31 (-0.52), ARQL: 1.40 (-0.08), APRI: 0.34 (-0.01)

BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.45 (+0.01), ENDP: 20.23 (-0.47), BSTC: 37.55 (+0.96), ARQL: 1.40 (-0.08)

ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:47AM CDT
ARIAD's (ARIA) decision to divest European operations should allow the company to focus on the U.S. market.
BSTC: 37.55 (+0.96), INCY: 80.81 (-0.29), ARQL: 1.40 (-0.08), ARIA: 10.19 (-0.15)

BioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2016 and provided a corporate update.
BSTC: 37.55 (+0.96)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Walmart Tops 2026 Recall List: 81 Notices, Food Issues Lead

Walmart Behind 81 Recalls: Scrutinizing 2026's Top Contender For an outfit that prides itself on shaking up shopping carts coast to coast, Walmart's stumble onto the recall hotseat this year is a head-scratcher. Imagine leading with 81 official recalls—that's more than a flash in the pan, it's the whole frying pan catching fire. Target and Costco aren't slouches, but...

AppLovin Faces Serious Investor Lawsuit Deadline

Investors' Trust Shaken: The AppLovin Controversy Well, what do we have here? Another day, another hefty lawsuit coming down the pike. The spotlight’s on AppLovin Corporation (NASDAQ: APP), where the Hagens Berman law sharks are sniffing blood in the water over what they claim are federal securities law violations. The core of this legal storm swirls around AppLovin's...

Betterness Expands Health Networks with $3.5M Boost

Defining a Health Revolution in the Heart of Miami Just when you think the fitness tech scene might be settling into its groove, along comes Betterness, Inc., shaking things up with another cool million in their pockets. I'm talking about their recent addition to their seed round, now sitting pretty at a robust $3.5 million. You can't ignore how they're taking a...

Koppers Faces SEC Scrutiny After Earnings Miss

Koppers' Third-Quarter Blues: Missing the Mark Koppers Holdings Inc. (NYSE: KOP) took a hard hit this quarter, missing Wall Street's earnings expectations by a mile. The adjusted earnings per share came in at just $0.77, while the suits down on Wall Street were expecting something closer to $1.34 to $1.37. Now, if you’re holding KOP in your portfolio, you're probably...

AI-Driven Software Growth Faces Profitability Hurdles

AI and Growth: A Tale of Two Strategies Is AI the superhero we’ve been waiting for, or just another fad? The KeyBanc Capital Markets' 2026 AI x Software Benchmark throws more questions into the ring than it answers. This benchmark isn't just numbers on a page; it's a pulse check on how AI is reshaping the software landscape. Seeing AI-native firms grow at a dizzying 34%...

MV Transportation Celebrates Leadership Nomination for FTA

MV Throws Support Behind Aesch for FTA Role In this wild world where public transit feels the heat from financial burdens, MV Transportation's recent move to support Mark Aesch for the Federal Transit Administration's top spot isn’t just a nod of approval—it's a full-blown trumpet blast. They're not just doling out a basic endorsement here; they're practically waving...

Maritime Launch's Bold Q3 Surge Amid Space Race

Rockets, Revenue, and a Bold New Path You ever hear about a spaceport tucked away in the toes of Nova Scotia, making waves with its third-quarter earnings? Well, that's exactly what's cooking over at Maritime Launch Services. These folks have managed to turn a zero into hero in a flash, reporting $5.6 million in revenue and a snug $3.5 million in net income for Q3 2026....

NueSynergy Secures Top Spot in HSA Provider Rankings

NueSynergy Earns its Stripes in 2026 It seems these days, healthcare costs are rising faster than you can say 'deductible.' In this chaotic landscape, a good HSA provider is worth its weight in gold. Enter NueSynergy, whose efforts have once again been acknowledged by Morningstar, a big name in the world of investment research. What Sets NueSynergy Apart? NueSynergy isn't...

Where Winds Meet Celebrates 1st Anniversary With New Region

A Staggering Universe Deepens: Hutuo's Introduction Just when you think you've seen it all, NetEase Games and Everstone Studio go and launch Hutuo, a compelling addition to the already sprawling universe of Where Winds Meet. On the occasion of its first global anniversary, this epic Wuxia ARPG throws players into the mud-soaked, steel-clashing chaos of a warzone, testing...

Timken Maintains Robust Dividend Streak in 2026

Timken Keeps Dividend Train Rolling You want to talk consistency? Timken Company just declared its quarterly dividend like clockwork. As a stockholder, that might just be your morning coffee fix before anything else. Notably, Timken's been on the NYSE since 1922, having cranked out 418 consecutive dividend payouts. That's like your grandpa never missing a Sunday golf...